SBLOF (Shin Nippon Biomedical Laboratories) PS Ratio: 1.79 (As of Jun. 29, 2026) — Near Median


SBLOF Shin Nippon Biomedical Laboratories Ltd SBLOF
77 GF Score
Price $9.16
GF Value $14.46
! 5 Warning Signs
View Full Analysis

What is Shin Nippon Biomedical Laboratories PS Ratio?

Shin Nippon Biomedical Laboratories SBLOF -2.13% 77 PS Ratio is 1.79 as of Jun. 29, 2026, which is 9% below its 10-year median of 1.97. GuruFocus rates SBLOF with a GF Score™ of 77/100 and a GF Value™ of $14.46. The stock has 5 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Shin Nippon Biomedical Laboratories ranks better than 72.5% on this metric.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Shin Nippon Biomedical Laboratories's share price is $9.1608. Shin Nippon Biomedical Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $5.13. Hence, Shin Nippon Biomedical Laboratories's PS Ratio for today is 1.79.

Good Sign:

Shin Nippon Biomedical Laboratories Ltd stock PS Ratio (=1.43) is close to 5-year low of 1.39.

The historical rank and industry rank for Shin Nippon Biomedical Laboratories's PS Ratio or its related term are showing as below:

SBLOF' s PS Ratio Range Over the Past 10 Years
Min: 1.15   Med: 1.97   Max: 6.53
Current: 1.43

During the past 13 years, Shin Nippon Biomedical Laboratories's highest PS Ratio was 6.53. The lowest was 1.15. And the median was 1.97.

SBLOF's PS Ratio is ranked better than
72.5% of 200 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.81 vs SBLOF: 1.43

Shin Nippon Biomedical Laboratories's Revenue per Sharefor the three months ended in Mar. 2026 was $1.72. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $5.13.

Warning Sign:

Shin Nippon Biomedical Laboratories Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Shin Nippon Biomedical Laboratories was 0.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 9.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 17.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 8.30% per year.

During the past 13 years, Shin Nippon Biomedical Laboratories's highest 3-Year average Revenue per Share Growth Rate was 22.20% per year. The lowest was -9.80% per year. And the median was -2.50% per year.

Back to Basics: PS Ratio


Shin Nippon Biomedical Laboratories  (OTCPK:SBLOF) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Shin Nippon Biomedical Laboratories PS Ratio Related Terms


Shin Nippon Biomedical Laboratories PS Ratio Historical Data

* Premium members only.

The historical data trend for Shin Nippon Biomedical Laboratories's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shin Nippon Biomedical Laboratories PS Ratio Chart

Shin Nippon Biomedical Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.98 4.56 2.39 1.84 1.81

Shin Nippon Biomedical Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.84 1.77 2.05 2.22 1.81

SBLOF vs TMO, DHR, IDXX: PS Ratio Comparison

For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shin Nippon Biomedical Laboratories PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's PS Ratio distribution charts can be found below:

* The bar in red indicates where Shin Nippon Biomedical Laboratories's PS Ratio falls into.


SBLOF
77GF Score
Shin Nippon Biomedical Laboratories Ltd SBLOF
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shin Nippon Biomedical Laboratories PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Shin Nippon Biomedical Laboratories's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=9.1608/5.128
=1.79

Shin Nippon Biomedical Laboratories's Share Price of today is $9.1608.
Shin Nippon Biomedical Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.13.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 1.79 mean?
Shin Nippon Biomedical Laboratories (SBLOF) has a PS Ratio of 1.79 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Shin Nippon Biomedical Laboratories and its competitors. This is near median its historical median of 1.97. Over the past decade, Shin Nippon Biomedical Laboratories' PS Ratio has ranged from 1.15 to 6.53. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #55 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 27.5%.
Is Shin Nippon Biomedical Laboratories' PS Ratio too high?
Shin Nippon Biomedical Laboratories' current PS Ratio of 1.79 is near median its 10-year median of 1.97. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 6.53. The Medical Diagnostics & Research industry median PS Ratio is 2.81. Shin Nippon Biomedical Laboratories' value of 1.79 is 36.3% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #55 out of 200 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #55 out of 200 companies for PS Ratio. This puts Shin Nippon Biomedical Laboratories in the upper half of its industry. The industry median PS Ratio is 2.81. Shin Nippon Biomedical Laboratories' value of 1.79 is 36.3% below this benchmark. Historically, Shin Nippon Biomedical Laboratories' own PS Ratio has ranged from 1.15 to 6.53 over the past decade. While the company's 10-year median is 1.97 vs. the industry median of 2.81, Shin Nippon Biomedical Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.81, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current PS Ratio of 1.79 is 36.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Shin Nippon Biomedical Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current PS Ratio is 1.79, which is near median its own 10-year median of 1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current PS Ratio of 1.79. The stock's GF Value™ is $14.46, compared to a current price of $9.16 — trading 36.6% below its estimated fair value. The current PS Ratio is 1.79, which is near median its 10-year median of 1.97 and 36.3% below the Medical Diagnostics & Research industry median of 2.81. Shin Nippon Biomedical Laboratories' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current PS Ratio is 1.79 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?

Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued. The current stock price of $9.16 is trading 36.6% below its estimated GF Value™ of $14.46.

Key valuation signals for SBLOF:

  • PS Ratio: 1.79 (near median its 10-year median of 1.97)
  • GF Value™: $14.46 vs. price of $9.16 (36.6% below fair value)
  • GF Score™: 77/100 with 5 warning signs
  • Industry Position: 36.3% below the Medical Diagnostics & Research median (#55 of 200)

No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shin Nippon Biomedical Laboratories Business Description

Other Exchanges 2395:JapanYB3:Germany
Address 8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
77GF Score

Get the complete analysis for SBLOF

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.16
Price
$14.46
GF Value